Industry News
Pharmaceutical Industry News
Headache Research Advances Though Cures Are Elusive
Research into these often mysterious and debilitating disorders has languished. That’s changing.
Biogen’s Aduhelm Sales Total $2 Million in Second Quarter
The drug from Biogen, called Aduhelm, is expected to generate billions in sales. It could also strain Medicare’s budget within a few years.
J&J’s COVID-19 shot scores safety backing from CDC experts but booster need left for FDA
J&J’s COVID-19 shot scores safety backing from CDC experts but booster need left for FDA nhigginsdunn Thu, 07/22/2021 - 16:32
Once conditional, Merck’s Keytruda, Eisai’s Lenvima win full approval for endometrial cancer
Once conditional, Merck's Keytruda, Eisai's Lenvima win full approval for endometrial cancer kdunleavy Thu, 07/22/2021 - 12:10
Biogen execs blame critics, the media for spurring ‘misinformation’ as Aduhelm launch lags expectations
Biogen execs blame critics, the media for spurring 'misinformation' as Aduhelm launch lags expectations nhigginsdunn Thu, 07/22/2021 - 11:25
Roche pharma chief pegs $2B boost to Polivy’s potential lymphoma expansion as drugmaker weathers biosimilars
Roche pharma chief pegs $2B boost to Polivy's potential lymphoma expansion as drugmaker weathers biosimilars aliu Thu, 07/22/2021 - 10:51
A $200M injection from the U.S. will allow Aspen to produce more Johnson & Johnson COVID-19 vaccines for Africa
A $200M injection from the U.S. will allow Aspen to produce more Johnson & Johnson COVID-19 vaccines for Africa kdunleavy Thu, 07/22/2021 - 10:27
Trade group trio raises drug shortage alarm as FDA ups its carcinogen testing efforts
Trade group trio raises drug shortage alarm as FDA ups its carcinogen testing efforts fkansteiner Thu, 07/22/2021 - 08:12
Pfizer’s immunology ambitions delayed—again—as JAK drugs fall victim to FDA’s protracted safety review
Pfizer's immunology ambitions delayed—again—as JAK drugs fall victim to FDA's protracted safety review aliu Thu, 07/22/2021 - 05:43
Drug Distributors and J.&J. Reach $26 Billion Deal to End Opioids Lawsuits
The agreement would allow funds to begin flowing from the companies to states and communities to pay for addiction and prevention services.
Done deal: Johnson & Johnson and 3 distributors agree to historic $26 billion opioid settlement
Done deal: Johnson & Johnson and 3 distributors agree to historic $26 billion opioid settlement kdunleavy Wed, 07/21/2021 - 16:38
Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations
Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations fkansteiner Wed, 07/21/2021 - 11:20
AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases
AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases nhigginsdunn Wed, 07/21/2021 - 11:05
With Biovac agreement, Pfizer and BioNTech extend their COVID-19 vaccine manufacturing network to Africa
With Biovac agreement, Pfizer and BioNTech extend their COVID-19 vaccine manufacturing network to Africa kdunleavy Wed, 07/21/2021 - 10:43
Is Entresto maker Novartis scared of Jardiance’s landmark heart failure win? Not really, exec says
Is Entresto maker Novartis scared of Jardiance's landmark heart failure win? Not really, exec says aliu Wed, 07/21/2021 - 10:34
Teva taps new North American commercial chief as key meds Ajovy, Austedo lag their rivals
Teva taps new North American commercial chief as key meds Ajovy, Austedo lag their rivals esagonowsky Wed, 07/21/2021 - 09:42
Catalent makes a $100M splash to add biologics drug substance firepower at Italian plant
Catalent makes a $100M splash to add biologics drug substance firepower at Italian plant fkansteiner Wed, 07/21/2021 - 09:16
Bluebird bio, reeling from Zynteglo safety scare, snags EU nod for new gene therapy against rare neurodegenerative disease
Bluebird bio, reeling from Zynteglo safety scare, snags EU nod for new gene therapy against rare neurodegenerative disease aliu Wed, 07/21/2021 - 08:05
Otezla maker Amgen challenges patient groups to help fix long-lasting psoriasis treatment gaps
Otezla maker Amgen challenges patient groups to help fix long-lasting psoriasis treatment gaps nhigginsdunn Wed, 07/21/2021 - 07:24
J.&J. Vaccine May Be Less Effective Against Delta, Study Suggests
Many who received the shot may need to consider boosters, the authors said. But federal health officials do not recommend second doses.